For mental health conditions, drugs are not always the answer. Patients might still get no better
outcomes and additional approaches may be needed. DTx offer not only a treatment for mental health conditions by themselves but also a secondary treatment to mental health conditions that coexist with chronic diseases like cancer, psoriasis, etc. This series of 2 meetings to discuss in detail with other senior leaders the current state of DTx in mental health, what indications are best suited to such interventions, and commercial opportunities that they present.
SESSION 1: September 7th
- Current DTx products in mental health: what are the most and least explored areas? What are the keys to success? What should we double down on?
SESSION 2: September 28th - Best routes to market for DTx companies in mental health (e.g partnerships with employers, pharma, payers, D2C, etc).
- Adoption and last-mile delivery challenges: industry perception and reception of these products (patients and physicians engagement so far), and last-mile distribution challenges.